title: New targets for treatment against HCV infection.
abstract: Owing to the tremendous effort from both academia and industry, drug development for hepatitis C virus (HCV) infection has been flourishing, with a range of pipeline compounds at various stages of development. Although combination of the recently launched serine protease inhibitors will further improve the response rate of current interferon-based therapy, some intrinsic limitations of these compounds and the tendency of resistance development by the virus, urge the development of alternative or additional therapeutic strategies. In this article we provide an overview of different host and viral factors which have emerged as new potential targets for therapeutic intervention using state-of-the-art technologies.
authors.affiliation: Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Room L-462, 's Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. q.pan@erasmusmc.nl
authors.forename: Qiuwei
authors.initials: Q
authors.lastname: Pan
authors.forename: Luc J W
authors.initials: LJ
authors.lastname: van der Laan
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D021983:Cyclophilins / Q000187:drug effects; D016679:Genome, Viral / Q000187:drug effects; D016174:Hepacivirus / Q000187:drug effects* / Q000502:physiology; D006526:Hepatitis C / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D035683:MicroRNAs / Q000187:drug effects; D058990:Molecular Targeted Therapy / Q000379:methods*; D053586:Virus Internalization / Q000187:drug effects; D018406:Virus Physiological Phenomena / Q000187:drug effects*; D014779:Virus Replication / Q000187:drug effects / Q000502:physiology
chemical_list: D000998:Antiviral Agents; D035683:MicroRNAs; D021983:Cyclophilins